IP Verse

Methods For Preventing Or Treating Allergy By Administering An Il-4R Antagonist

Patent No. EP3506931 (titled "Methods For Preventing Or Treating Allergy By Administering An Il-4R Antagonist") was filed by Regeneron Pharmaceuticals on Aug 31, 2017. The application was issued on Jul 31, 2024.

Patent Summary

Dupilumab is a therapeutic antibody for treating allergies, specifically targeting IL-4Rα. The drug achieves this by selectively binding to the IL-4Rα receptor, preventing the activation of IL-4 and IL-13, key cytokines involved in allergic responses. Dupilumab is administered subcutaneously and has been shown to effectively reduce serum allergen-specific IgE levels in patients with moderate-to-severe allergies, including asthma and food allergies, by up to 50% compared to baseline. It is particularly effective in patients with sensitization to multiple allergens.

Patent Family

Patent family tree
Statuses, jurisdictions and citation links are shared on request.

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
BOULT WADE TENNANTApr 30, 2025BOULT WADE TENNANT
HAMPTON KNOWLESApr 30, 2025D YOUNG
SECERNAApr 30, 2025SECERNA
LUIGIApr 29, 2025TER MEER STEINMEISTER & PARTNER GBR

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

EP3506931

REGENERON PHARMACEUTICALS
Application Number
EP17771619A
Filing Date
Aug 31, 2017
Status
Granted And Under Opposition
Jun 27, 2024
Publication Date
Jul 31, 2024
External Links
Slate, Register , Google Patents